Literature DB >> 23053689

Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations.

Amélie Loctin1, François Bailly, Davy Laroche, Christian Tavernier, Jean-Francis Maillefert, Paul Ornetti.   

Abstract

Bone marrow aspiration (BMA) can be performed by rheumatologists for diagnostic purposes in clinical practice. The aim of the study was to assess professional practices of hospital-based rheumatologists with regard to BMA in order to identify the relevant indications. A retrospective observational study in patients hospitalised in a French university hospital was conducted between 2005 and 2011. All of the patients who had a BMA in the rheumatology department during the study period were included. Clinical indication, number and results of BMA and of bone marrow biopsy (BMB) were collected. Stage and treatment of the haematological disease implemented following the BMA were described. Two hundred fifty-seven BMAs and 79 BMBs were performed during the study period. Of the BMAs, 14.1 % were pathological: myeloma (n = 12), malignant B cell non-Hodgkin's lymphoma (n = 6), myelodysplastic syndrome (n = 6), chronic lymphoid leukaemia (n = 4), Waldenstrom's disease (n = 3), chronic myelomonocytic leukaemia (n = 2), hairy cell leukaemia (n = 1) and acute lymphoblastic leukaemia (n = 1). Eight of the 14 pathological BMBs were associated with normal BMA. BMAs were performed equally for gammaglobulin abnormalities (monoclonal peak = 45 % of indications, hypogammaglobulinemia = 6 %) and for other reasons (haemogram abnormality = 24 %, skeletal osteolysis = 6 %, unexplained inflammatory syndrome = 5 %, lymph node disease = 4 % and others). In clinical rheumatology, BMA may reveal two major types of malignant haematological diseases: myeloma with poor prognostic factors justifying polychemotherapy and autologous grafts and, in contrast, slowly evolving B cell lymphoid haemopathies. Given the additional risk in some types of chronic inflammatory rheumatism, BMB should be performed more frequently in certain specific situations (skeletal or lymph node tumour and unexplained inflammatory syndrome).

Entities:  

Mesh:

Year:  2012        PMID: 23053689     DOI: 10.1007/s10067-012-2097-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

Review 1.  Needle aspiration and biopsy in the diagnosis and monitoring of bone marrow diseases.

Authors:  A Hodges; M J Koury
Journal:  Clin Lab Sci       Date:  1996 Nov-Dec

2.  Bone marrow aspiration and biopsy.

Authors:  Daniele Focosi
Journal:  N Engl J Med       Date:  2010-01-14       Impact factor: 91.245

3.  Bone marrow trephine biopsy.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

Review 4.  Hematologic manifestations of primary Sjögren's syndrome.

Authors:  P Manganelli; P Fietta; F Quaini
Journal:  Clin Exp Rheumatol       Date:  2006 Jul-Aug       Impact factor: 4.473

Review 5.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

6.  Metastatic tumor: the complementary role of the marrow aspirate and biopsy.

Authors:  B Atac; C Lawrence; S N Goldberg
Journal:  Am J Med Sci       Date:  1991-10       Impact factor: 2.378

7.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 8.  Bone marrow involvement by hodgkin and non-hodgkin lymphomas.

Authors:  Qian-Yun Zhang; Kathryn Foucar
Journal:  Hematol Oncol Clin North Am       Date:  2009-08       Impact factor: 3.722

9.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

10.  UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Jenny Bird; Judith Behrens; Jan Westin; Ingemar Turesson; Mark Drayson; Robert Beetham; Shirley D'Sa; Richard Soutar; Anders Waage; Nina Gulbrandsen; Henrik Gregersen; Eric Low
Journal:  Br J Haematol       Date:  2009-08-10       Impact factor: 6.998

View more
  2 in total

1.  Indications for bone marrow examinations in rheumatology.

Authors:  Hava Üsküdar Teke; Döndü Üsküdar Cansu; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2019-04-30       Impact factor: 2.631

2.  Contribution to diagnosis and treatment of bone marrow aspirate results in critically ill patients undergoing bone marrow aspiration: a retrospective study of 193 consecutive patients.

Authors:  Laure Calvet; Bruno Pereira; Anne-Françoise Sapin; Gabrielle Mareynat; Alexandre Lautrette; Bertrand Souweine
Journal:  J Intensive Care       Date:  2017-12-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.